What predicts successful nonoperative management with botulinum toxin for anal fissure?

Am J Surg. 2020 Mar;219(3):442-444. doi: 10.1016/j.amjsurg.2019.10.012. Epub 2019 Oct 11.

Abstract

Background: Botulinum toxin has been established as a non-surgical alternative for chronic anal fissures. There is a paucity of data regarding which patients benefit most from this intervention.

Methods: We retrospectively collected data from all cases of chronic anal fissures treated with botulinum toxin over seven years to identify predictors of success. Non-responders were defined as any subsequent surgery or reporting satisfaction as poor or fair.

Results: Of 91 patients, 60% (n = 55) were responders and 26% (n = 25) underwent subsequent surgery. There were significantly more females among responders (78% vs. 55%, p = 0.02). A higher body mass index tended towards significance among non-responders (30 ± 7 vs. 27 ± 6, p = 0.08). High satisfaction at the first visit was associated with no subsequent surgery (18% vs. 45%, p = 0.002).

Conclusions: Botulinum toxin can be successfully used to treat anal fissures in a majority of patients. Primary predictors of success were female sex, satisfaction at the first post-procedure visit and there was a tendency towards a lower body mass index.

Keywords: Anal fissure; Botulinum toxin; Lateral internal sphincterotomy.

MeSH terms

  • Adult
  • Botulinum Toxins, Type A / therapeutic use*
  • Chronic Disease
  • Female
  • Fissure in Ano / drug therapy*
  • Fissure in Ano / surgery
  • Humans
  • Injections, Intralesional
  • Male
  • Michigan
  • Middle Aged
  • Neuromuscular Agents / therapeutic use*
  • Patient Satisfaction
  • Retrospective Studies
  • Sex Factors

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A